UTRECHT - Merus N.V. (Nasdaq: MRUS) ('Merus', 'the Company', 'we', or 'our'), a clinical-stage oncology company developing innovative, full-length multispecific antibodies, today announced that clinical data from its Phase 1 dose escalation study of MCLA-158 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium (ASCO GI) annual meeting being held virtually from January 15-17, 2021.

'We are pleased that MCLA-158 treatment was well tolerated in patients and that we have reached the recommended phase 2 dose,' said Andrew Joe, MD, Chief Medical Officer of Merus. 'The dose expansion phase is continuing with enrollment of patients with gastric and other non-CRC cancers.'

About Merus N.V.

Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Multiclonics are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.

Contact:

Jillian Connell

Tel: 617-955-4716

Email: j.connell@merus.nl

(C) 2021 Electronic News Publishing, source ENP Newswire